Lundbeck to make bond debut after drug news
H Lundbeck, the Danish pharmaceutical company, has mandated banks for a five year debut euro benchmark from its new bond programme, after gaining US regulatory approval for a new migraine treatment.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: